Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Clinical conditions and evidence for psychedelic therapies
12
Conditions
4
RCT Evidence
3
Categories
6
Substances
Affects approximately 30% of patients with major depression (10-12 million people in the US alone). Defined as failure to respond adequately to 2 or more antidepressant trials.
Third-line antidepressants, augmentation strategies (lithium, thyroid hormone, atypical antipsychotics), ECT, TMS, VNS. Response rates decline with each failed trial.
IV ketamine (0.5mg/kg, rapid onset within hours) is the most established. Psilocybin-assisted therapy shows remarkable results in Phase 2 trials with lasting effects from just 1-2 sessions. Both work through distinct mechanisms from traditional antidepressants.
Ketamine: 50-70% response within hours (Zarate et al., 2006). Psilocybin: 71% response, 54% remission at 4 weeks (Davis et al., 2021). Both show rapid onset compared to weeks for SSRIs.
Lifetime prevalence of 6-8% in the general population. Up to 20-30% in combat veterans and first responders. Approximately 12 million US adults have PTSD in a given year.
Trauma-focused CBT, EMDR, prolonged exposure therapy, CPT. SSRIs (sertraline, paroxetine) are first-line pharmacotherapy. Only ~50% of patients respond adequately, and many retain significant residual symptoms.
MDMA-assisted therapy (MAPS protocol) is the most advanced psychedelic treatment for PTSD. MDMA creates a state of reduced fear and enhanced trust that allows trauma processing without overwhelming anxiety. 3 medicine sessions over 12 weeks with intensive integration.
MAPP1 Phase 3: 67% no longer met PTSD criteria at primary endpoint. 71.2% response rate. Effect size d=0.91. MAPP2 confirmed efficacy across diverse populations. FDA Breakthrough Therapy designation.
Global lifetime prevalence of 15-20%. WHO ranks depression as the leading cause of disability worldwide. 280 million people affected globally. In Switzerland, 12-month prevalence is approximately 7%.
SSRIs/SNRIs as first-line, psychotherapy (CBT, IPT), combination therapy. 30-40% of patients do not respond adequately to first-line treatment. Full remission is achieved in only 30-40% of cases with initial treatment.
Psilocybin shows the strongest evidence in MDD. Just 2 sessions produced rapid, sustained antidepressant effects. Ketamine/esketamine for acute stabilization. Ayahuasca showed rapid effects in a single-session RCT. All three substances target different neurobiological pathways than traditional antidepressants.
Psilocybin: effect size d=2.5 vs. waitlist (Davis et al., 2021). Comparable to or exceeding esketamine in head-to-head comparison (Goodwin et al., 2022 NEJM). Ayahuasca: significant improvement at 7 days in RCT (Palhano-Fontes et al., 2019).
Lifetime prevalence of 5-6%. 12-month prevalence approximately 3%. More common in women (2:1 ratio). Frequently comorbid with depression.
CBT, SSRIs/SNRIs, buspirone, benzodiazepines (short-term). Response rates around 50-60%. Many patients experience only partial relief.
Psilocybin studies in cancer-related anxiety demonstrate significant and lasting anxiety reduction. LSD showed anxiolytic effects in the landmark Gasser et al. (2014) Swiss study. Mechanism may involve disruption of rumination circuits and enhanced emotional processing.
Griffiths et al. (2016): Psilocybin produced sustained anxiety decreases at 6-month follow-up in cancer patients. Gasser et al. (2014): LSD-assisted psychotherapy reduced anxiety in life-threatening illness.
Affects 30-50% of patients with advanced cancer or terminal illness. Existential distress, death anxiety, and demoralization significantly reduce quality of life in the final months.
Palliative psychiatry: SSRIs/SNRIs, benzodiazepines, meaning-centered psychotherapy, dignity therapy. Treatment options are limited and often have slow onset relative to prognosis.
Psilocybin-assisted therapy has produced some of the most compelling results in all of psychedelic research. A single high-dose session can produce rapid, sustained reductions in anxiety and depression that persist for months. Many participants report a profound shift in their relationship with mortality, often describing mystical experiences that transform existential dread into acceptance.
Griffiths et al. (2016): 80% showed clinically significant decreases in depression/anxiety at 6 months. Ross et al. (2016): Single psilocybin dose produced rapid, sustained anti-anxiety effects in cancer patients. Both studies showed unprecedented durability of response.
Lifetime prevalence approximately 0.5-2% (predominantly female, increasingly diagnosed in males). Highest mortality rate of any psychiatric disorder (5-10% over 10 years). Chronic courses are common with limited effective treatments.
Family-based therapy (FBT) for adolescents, CBT-E for adults, nutritional rehabilitation, weight restoration. No FDA-approved pharmacotherapy specifically for AN. Treatment-resistant cases have very poor prognosis.
Psilocybin may disrupt the rigid cognitive patterns and distorted body image characteristic of AN by increasing cognitive flexibility and emotional processing. Early trials focus on body image flexibility, psychological flexibility, and reducing obsessive food-related thoughts.
Spriggs et al. (2021): Case series showed psilocybin reduced eating disorder psychopathology. COMP360 Phase 2 trial (Compass Pathways) enrolling for AN. Preliminary data suggests improvements in psychological flexibility and body image.
Lifetime prevalence 2-3%. Chronic and debilitating. Up to 40-60% of patients do not respond adequately to first-line SSRI therapy. Average delay to correct diagnosis is 7-10 years.
ERP (Exposure and Response Prevention), high-dose SSRIs (often 2-3x depression doses), clomipramine. Augmentation with antipsychotics. DBS for severe refractory cases. Treatment response is often partial.
Psilocybin targets the serotonin system, which is centrally involved in OCD pathology. By acutely stimulating 5-HT2A receptors and disrupting cortico-striato-thalamo-cortical circuits, psilocybin may 'reset' the repetitive thought loops that characterize OCD. Early evidence suggests rapid, dose-dependent symptom reduction.
Moreno et al. (2006): All 9 subjects showed marked decreases in OCD symptoms with psilocybin (Y-BOCS reductions of 23-100%). Onset within hours. Yale Phase 2 trial (NCT03300947) in progress.
Lifetime prevalence 7-13%. One of the most common anxiety disorders. Average age of onset is 13 years. Often comorbid with depression and substance use disorders.
CBT (especially exposure-based), SSRIs/SNRIs, MAOIs (phenelzine), benzodiazepines (short-term). Response rates 50-65%. Many patients retain significant social avoidance despite treatment.
MDMA enhances prosocial feelings, reduces social threat perception, and increases empathy β directly targeting the core features of social anxiety. Psilocybin may reduce self-referential processing and social evaluative fears through default mode network disruption. Particularly promising for autistic adults with social anxiety.
Danforth et al. (2018): MDMA-assisted therapy for social anxiety in autistic adults showed significant and lasting reductions. Phase 2 trial ongoing. Psilocybin studies show reduced amygdala response to social threat stimuli.
Affects approximately 5-8% of the global adult population. 14.5 million people in the US (NSDUH 2019). Leading cause of preventable death. Only about 7.5% of patients receive any treatment.
Behavioral therapies (CBT, motivational interviewing, 12-step), pharmacotherapy (naltrexone, acamprosate, disulfiram). 1-year relapse rates remain around 40-60% even with optimal treatment.
Psilocybin-assisted therapy has shown promise in reducing heavy drinking. The mechanism may involve disrupting entrenched neural patterns of addictive behavior and enhancing motivation for change through insights gained during the psychedelic experience. Historical LSD research (1950s-60s) showed positive results for alcoholism.
Bogenschutz et al. (2022): Psilocybin significantly reduced percentage of heavy drinking days vs. active placebo in RCT. Meta-analysis of 1960s LSD trials (Krebs & Johansen, 2012) showed significant benefit for alcohol misuse.
1.3 billion tobacco users worldwide (WHO). Leading preventable cause of death globally (8 million deaths/year). 6-month quit rates with best available treatments (varenicline) are approximately 25-35%.
NRT (patches, gum, lozenge), varenicline (Champix), bupropion, behavioral counseling. Even with combination therapy, long-term abstinence rates are modest.
Psilocybin-assisted therapy combined with CBT for smoking cessation at Johns Hopkins showed remarkable quit rates. The combination of powerful motivational insights during the psychedelic experience with structured behavioral change support appears synergistic.
Johnson et al. (2014): 80% abstinence at 6 months (open-label pilot, n=15). Johnson et al. (2017): 67% confirmed abstinent at 12 months. These rates substantially exceed any current pharmacotherapy. Phase 2 RCT ongoing.
16 million people affected globally. Over 100,000 opioid overdose deaths annually in the US alone (2021-2023). The opioid crisis is one of the most severe public health emergencies in modern history.
MAT: buprenorphine (Suboxone), methadone, naltrexone (Vivitrol). Behavioral therapies. MAT is effective but requires long-term maintenance, and access remains limited. Retention in treatment is a major challenge.
Ibogaine is the primary psychedelic candidate for opioid addiction. A single flood dose (15-20mg/kg) can dramatically reduce or eliminate withdrawal symptoms and cravings within hours. The 24-36 hour experience involves a 'life review' visionary state. CRITICAL SAFETY CONCERN: Ibogaine carries significant cardiac risk (QT prolongation, fatal arrhythmia) and requires ICU-level monitoring.
Brown & Alper (2018): 50% abstinent at 12 months in observational study. Noller et al. (2018): Significant reduction in SOWS withdrawal scores. No Phase 3 RCTs completed yet. Multiple deaths reported in unsupervised settings β cardiac monitoring is essential.
Prevalence approximately 0.1% of the population. Known as 'suicide headaches' due to extreme pain intensity (often rated 10/10). Episodic form (80%): attack clusters lasting weeks to months. Chronic form (20%): attacks for >1 year without remission.
Acute: high-flow oxygen (100%, 12-15 L/min), sumatriptan injection. Preventive: verapamil, lithium, corticosteroids (short-term bridge), occipital nerve blocks. Many patients are refractory to standard treatments.
Patient-driven research (ClusterBusters) has reported that sub-hallucinogenic doses of psilocybin or LSD can abort cluster cycles and prevent attacks for weeks to months. Even a single dose may terminate an entire cluster period. This is one of the most consistently reported patient-discovered therapeutic applications of psychedelics.
Schindler et al. (2015): 19/26 patients reported cluster period termination with psilocybin. Sewell et al. (2006): Survey showed 25/53 psilocybin users reported remission of cluster period. Yale RCT in progress.